Accurate assessment and standardized treatment of interstitial cystitis

For many patients suffering from interstitial cystitis/bladder pain syndrome (IC/BPS), a diagnosis is just the starting point of a long treatment path. Faced with repeated episodes of frequent urination, urgency, pain or pressure in the lower abdomen or pelvic area, what patients want to know most urgently is: What should they do next? What treatment plan is best for me? In the Pudong area of Shanghai, the diagnosis and treatment of this complex chronic disease is undergoing profound changes from "experience-driven" to "precise stratification".

Traditionally, the diagnosis of interstitial cystitis has relied heavily on exclusion, which means that after excluding other clear causes such as infection, stones, and tumors, it is combined with typical symptoms and cystoscopy results (such as Hunner's ulcer or spotting bleeding of the bladder mucosa) to make a diagnosis. However, more and more clinical practice and research have shown that IC/BPS is not a single disease, but a group of heterogeneous syndromes with different potential etiologies, pathophysiological mechanisms, and clinical manifestations. This is like having a "fever". The reason behind it may be bacterial infection, viral infection or autoimmune disease. The treatment options are naturally very different. Therefore, a "one-size-fits-all" treatment for IC/BPS often has poor results and may even aggravate the pain of some patients.

Recognizing this, leading centers in the field of diagnosis and treatment of urinary dysfunction diseases, such as the Department of Urology, Pudong Gongli Hospital Affiliated to Shanghai Health Medical College, are committed to building a multi-dimensional and accurate evaluation system. The core idea of this system is to regard the patient as a whole and "three-dimensional portrait" from multiple levels, thus providing a solid basis for subsequent individualized treatment.

The first is an in-depth assessment of the symptom phenotype. This is not just about recording "how many times of frequent urination" and "how much pain is", but through standardized questionnaires and detailed doctor-patient communication, a comprehensive assessment of the nature of pain (burning, tingling, pressure), inducing and alleviating factors, relationship to the urination cycle, and accompanying intestinal symptoms, sexual function effects, sleep quality and emotional state. For example, in some patients, pain is highly related to bladder filling and is significantly relieved after urination; in some patients, pain persists and has little to do with bladder capacity. These two different phenotypes may point to different neural sensitization mechanisms or pelvic floor muscle dysfunction.

Secondly, it is objective evaluation with the help of advanced imaging technology. In addition to routine urinary ultrasound and urodynamic examinations, high-resolution magnetic resonance imaging (MRI) technology, especially special sequence scans for pelvic floor and brain function, is playing an increasingly important role. Pelvic floor MRI can clearly display the morphological abnormalities of pelvic floor muscles, ligaments and nerves; while functional magnetic resonance (fMRI) can reveal abnormal activation or connection changes in related functional areas of the brain (such as anterior cingulate gyrus and insular cortex) in chronic pain states, understanding the persistence of pain from the perspective of "central sensitization". This imaging evaluation "from the pelvic floor to the brain" opens a new window for understanding the complex neural mechanisms of IC/BPS.

The third is metabolomic and immunological evaluation that goes deep into the molecular level. By analyzing patients 'urine and blood samples and detecting specific metabolite profiles, inflammatory factors (such as cytokines, chemokines) and autoantibody levels, potential metabolic abnormalities, immune disorders, or microinflammatory states can be explored. For example, levels of mast cell activation markers such as histamine and methylhistamine in the urine of some patients are significantly elevated, suggesting that abnormal activation of mast cells in the bladder wall may be a key link in its pathogenesis. The discovery of such biomarkers not only helps in disease typing, but also provides a direct basis for targeted therapies such as the use of mast cell stabilizers.

At the Department of Urology at Shanghai Pudong Gongli Hospital, these assessments are not carried out in isolation, but are integrated and analyzed through a multidisciplinary collaborative team (MDT). The team brought together experts in multiple fields such as urology, pain, imaging, laboratory, and psychology to jointly "consult" each patient and draw an exclusive "disease map" based on multi-dimensional data. This kind of deep interdisciplinary integration reflects the differentiated advantages of this department as a national key clinical specialty and a key discipline in Shanghai City. It ensures the systematicness of assessment and the reliability of conclusions, and avoids the limitations of a single disciplinary perspective.

Only based on the stratification of precise assessment can a standardized and individualized treatment "blueprint" be drawn. Treatment no longer starts with simple oral drugs, but enters a standardized process with clear structure and step-by-step progress based on the evaluation results.

The first level of basic treatment focuses on patient education and behavioral adjustment. These include bladder training (gradually lengthening the interval between urinations by timed urinations), diet adjustments (identifying and avoiding foods that may aggravate symptoms, such as caffeine, alcohol, acidic fruits, artificial sweeteners, etc.), stress management and pelvic floor physical therapy. For patients with significant pelvic floor muscle hypertonia or trigger points, biofeedback treatment, manual release and home exercise under the guidance of a professional pelvic floor rehabilitation therapist are crucial.

The second level of drug treatment is accurately selected based on evaluation and classification. For patients with inflammatory or immune factors, hydroxyzine (antihistamine), amitriptyline (regulating neurotransmitters) or immunomodulators may be used; for patients with neuropathic pain, gabapentin, pregabalin and other neuroregulatory drugs may be a better choice; For patients with evidence of bladder epithelial dysfunction (glycosaminoglycan layer defect), bladder instillation of drugs such as sodium hyaluronate or heparin to help repair and protect the bladder mucosal barrier is a direct treatment for the cause. The Department of Urology of Shanghai Pudong Gongli Hospital emphasizes evidence-based and typing in drug selection, and closely monitors efficacy and side effects.

The third level of interventional treatment is suitable for moderate to severe patients who do not respond well to basic treatment and medical treatment. These include hydrodilation under cystoscope (which relieves some patients 'symptoms in the short term), laser or electrocautery treatment of Hunner's ulcer, and more advanced sacral nerve modulation (bladder pacemaker). Sacral nerve modulation improves bladder urine storage and relieves pain by implanting a tiny stimulator that sends slight electrical pulses to regulate abnormal signals in the sacral nerve. The department is at the forefront of innovative device applications across medical and industrial areas and is able to provide this advanced treatment option to eligible patients.

The fourth level of multi-modal pain management runs throughout. Recognizing that chronic pain itself has become a disease, integrate the resources of pain department and psychology department, adopt cognitive behavioral therapy, mindful decompression, and joint multi-modal analgesia programs when necessary to help patients break the vicious cycle of "pain-anxiety-more pain" and improve overall quality of life.

It is worth emphasizing that all treatments are nested within an integrated chronic disease management framework. The intelligent follow-up management platform built by the Department of Urology of Shanghai Pudong Gongli Hospital allows patients to regularly provide online feedback on symptom changes, medication status and quality of life scores. The doctor team can remotely monitor patient progress, adjust treatment plans in a timely manner, and realize the transition from "one visit" to "whole process management". This model is particularly suitable for chronic diseases like IC/BPS, which ensures continuity and responsiveness of treatment and allows patients to feel continuous support.

In addition, the multi-center real-world research led by the department is continuously verifying and optimizing this multi-dimensional evaluation and hierarchical treatment system. By collecting clinical data from a large number of China patients, it aims to establish disease classification standards and treatment paths that are more suitable for the China population, and promote the entire field from experience to precision. For patients in Pudong and even Shanghai, this means that they can obtain nearby standardized diagnosis and treatment services that are in line with international frontiers and based on local clinical evidence.

All in all, in the face of the problem of interstitial cystitis/bladder pain syndrome, the concept of modern diagnosis and treatment has undergone a fundamental change. Through multi-dimensional and precise assessment of symptom phenotypes, imaging characteristics, metabolic and immune markers, scientific stratification of heterogeneous patient groups, and then matching a stepped and individualized comprehensive treatment plan is the key to improving efficacy and improving prognosis. Relying on the platform advantages of key disciplines such as the Department of Urology at Pudong Gongli Hospital Affiliated to Shanghai Health Medical College, Shanghai Pudong Area is demonstrating strong integration and innovation capabilities and clinical service capabilities in the field of urinary dysfunction diseases, especially in the precise diagnosis and treatment of IC/BPS and chronic disease management., providing patients who suffer from them with a clearer, more scientific and more promising treatment path.